Mahesh Krishnan

Mahesh Krishnan discloses dealings in 2 companies, chiefly Halozyme Therapeutics, Inc. and Chinook Therapeutics, Inc. In total, 7 filings cover trades dated from 1 April 2023 to 29 June 2026.

Sales make up the whole of the open-market record (2 sales, €499k). The rest of the record consists of 2 share grants and 2 option exercises. Since January 2026: no purchases and 1 sale on the market.

The newest entry dates from 30 June 2026: an open-market sale of €480k, in Halozyme Therapeutics, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.